TTrialPathMatch Me to Trials
← Back to trials
RecruitingObesityOverweight

Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

Eligible age

18–70 yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.

Sponsor: Amgen

You may qualify if…

  • ✓ 18 to 70 years of age.
  • ✓ Body Mass Index (BMI) ≥ 25 at screening.
  • ✓ BMI ≥ 23 for Asian participants at screening.
  • ✓ Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise.
  • ✓ Stable dose of weekly GLP-1RA.
  • ✓ Stable gastrointestinal (GI) tolerability.
  • ✓ Contraception for females.
  • ✓ Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism.

You may not qualify if…

  • ✕ Type 1/Type 2 diabetes mellitus (DM).
  • ✕ Obesity induced by other endocrine disorder (ex: Cushing's syndrome).
  • ✕ History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ.
  • ✕ Acute \& chronic pancreatitis within 1 year.
  • ✕ Uncontrolled thyroid disease.
  • ✕ Gastroparesis or gastric outlet obstruction.
  • ✕ Surgery for obesity in the last 6 months.
  • ✕ Heart attack within 3 months.

Where it's recruiting

Arizona

Phoenix

California

Montclair

Florida

Daytona Beach · Hialeah · Maitland

Kentucky

Lexington

Tennessee

Knoxville

Texas

Dallas

Wisconsin

Madison

Source: ClinicalTrials.gov · NCT07908316 · last updated 2026-11-02

Comparing the Extent to Which Maridebart Cafraglutide is Made Availabl · TrialPath